Navigation Links
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Date:4/8/2011

TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME).  The companies are extending their development program for VEGF Trap-Eye in DME after promising results in the global Phase 2 DME program.

The first Phase 3 trial in DME, named VIVID-DME, is being led by Bayer HealthCare and has started in Australia.  The trial will also be conducted in Europe and Japan.  A second study led by Regeneron, named VISTA-DME, is expected to begin later in 2011 in the United States, Canada, and other countries.  

"Clinically significant DME is a leading cause of vision loss in adults under the age of 50 suffering from diabetes," said Dr. Kemal Malik, Head of Global Development and member of the Bayer HealthCare Executive Committee.  "After reporting positive results from our global Phase 3 program (VIEW 1 and VIEW 2 studies) for the treatment of the neovascular form of age-related macular degeneration (wet AMD), we are pleased to start a Phase 3 program with VEGF Trap-Eye in DME which may help to address this significant unmet medical need."

The Phase 3 program in DME expands the companies' global development collaboration for VEGF Trap-Eye.  The companies announced positive data for two Phase 3 studies in patients with wet AMD in November 2010 and for the first of two Phase 3 studies in patients with Central Retinal Vein Occlusion (CRVO) in December 2010.

About the Phase 3 DME Program

The VIVID-DME study (VEGF Trap-Eye In Vision Impairmen
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 STAAR Surgical Company (NASDAQ: ... marketer of minimally invasive ophthalmic products, today announced that ... review the Company,s recent financial results and business developments ... will present at the 38 th Annual Deutsche ... at the Westin Waterfront Hotel on Wednesday, May ...
(Date:5/20/2013)... GENEVA , May 21, 2013 ... Health Assembly, where world,s health ministers gather to address ... Mental and neurological disorders (MNDs) affect 700 ... global non-communicable disease (NCD) burden ,Do You ... understand the role each can play to collectively address ...
(Date:5/20/2013)... Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Directors declared, at its meeting on May 16, 2013, ... for the third quarter of fiscal 2013.  The dividend ... of record on June 7, 2013. About ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Landauer, Inc. Declares Regular Cash Dividend 2
... March 8, 2012 , Quality of Life ... available treatment fails in two thirds of patients ... Pevion Biotech AG today announced results from a large, ... vulvovaginal candidiasis (RVVC) patients. It is the first time that ...
... Inc. (Nasdaq: BIOD ) today announced that ... will present a corporate update at the ROTH 24th Annual ... 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). ... Conference will be held March 11-14, 2012, at the ...
Cached Medicine Technology:Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 2Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 3Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 4
(Date:5/21/2013)... significantly more likely than their normal-weight counterparts to ... disrupts continuity of care and leads to more ... , The practice of "doctor shopping" among overweight ... with the health care system, whether that be ... advice by providers, or improperly sized medical equipment ...
(Date:5/21/2013)... Children using the abutment-free implantable bone ... results comparable to the traditionally used, competitive abutment ... to a new study. , “The results are ... performs just as well as technology with a ... says Jim Kasic, president and CEO of Sophono. ...
(Date:5/21/2013)... News) -- Urban elementary school children with poorly ... and suffer academically, new research indicates. "In ... nine, we found that compromised lung function corresponded ... performance," said study author Daphne Koinis-Mitchell, an ... Brown University,s Alpert Medical School in Providence, R.I. ...
(Date:5/21/2013)... nanoparticles are usually toxic to cells, but cancer ... Clinic researchers found out why, and determined how ... cells. The discovery is detailed in the current ... Chemistry ., "This study identifies a novel mechanism ... cell death or apoptosis which should occur when ...
(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that ... the company has achieved its overall goal of becoming a ... to move Hammerhead Bicycles from a house brand to a ... , Robertson explained that the bike shop will go forward ... on all things 29er and 650b. , “The ...
Breaking Medicine News(10 mins):Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 3Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Hammerhead Bicycles Now a Standalone Brand 2
... Medical Record/Practice Management Software Company Aimed at Giving ... HILLS, Mich., May 27 gloStream, a healthcare ... Office embedded electronic medical record ("EMR") and practice ... closed on a $7.5 million series B financing ...
... When Chicago Blackhawk,s leading scorer Martin Havlat returned ... Conference Final after sustaining a concussion only two days ... to a new study by St. Michael,s Hospital neurosurgeon ... of minor league hockey players who did not know ...
... to healthier livesST. LOUIS, May 27 Nurse Response ... new consumer health tool that will complement the quality ... Response will offer the Healthwise Knowledgebase, an online consumer ... to access over 7,000 health topics online. , ...
... York, NY / Los Angeles, CA: Stand Up ... aimed at getting new cancer treatments to patients in ... the first round of three-year grants that total ... Teams. The majority of these funds were raised in ...
... The Institute for Palliative Medicine plays unique roleSAN DIEGO, ... Irwin, M.D., Ph.D., Director of the Palliative Care Psychiatry ... been elected as a Member of The American College ... one of only 750 practicing psychiatrists nationwide who have ...
... for stricter regulatory approval requirements and continuity of product supply. ... ... A recent report released by Wolters Kluwer Health predicts that by ... will be filled with generic drugs. This march to generics ...
Cached Medicine News:Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 2Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 3Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 4Health News:Minor league hockey players unable to identify concussion symptoms, study says 2Health News:Minor league hockey players unable to identify concussion symptoms, study says 3Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 2Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 3Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 4Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 5Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 6Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 7Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 8Health News:San Diego Psychiatrist Scott Irwin Honored With National Recognition 2Health News:San Diego Psychiatrist Scott Irwin Honored With National Recognition 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 2Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 4Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 5
VG2 PLIF (Parallel) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit cor...
An all-cortical structure provides the structural benefits of cortical bone. Precision machined to exact specifications to promote healthy lordosis and vertebral body distraction....
Solid cortical spacers with a natural anatomic fibular shape....
... Allografts are comprised of a ... strength and an enlarged center ... of preferred bone graft material ... instruments facilitate the insertion of ...
Medicine Products: